In biotech companies, the success of a new therapy depends not only on clinical efficacy but also on how effectively you engage key opinion leaders (KOLs). Ultimately, they are the ones who will adopt it in clinical practice and champion it on podiums and among peers. ... Read this blog
Recommended
